V591
Biological
Merck Sharp & Dohme Corporation
Total Payments
$2.5M
Transactions
80
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $2.5M | 80 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.5M | 80 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1,Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 COVID-19 Vaccine in Healthy Younger and Older Participants | Merck Sharp & Dohme Corporation | $2.4M | 0 |
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V591 MV SARS-CoV-2, Live, Recombinant in Healthy Individuals 16 Years of Age or Older | Merck Sharp & Dohme Corporation | $175,440 | 0 |
Top Doctors Receiving Payments for V591
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Hollywood, FL | $2.5M | 80 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $2.5M
- Total Doctors 0
- Transactions 80
About V591
V591 is a biological associated with $2.5M in payments to 0 healthcare providers, recorded across 80 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2020 to 2020. In 2020, $2.5M was paid across 80 transactions to 0 doctors.
The most common payment nature for V591 is "Unspecified" ($2.5M, 100.0% of total).
V591 is associated with 2 research studies, including "A Phase 1,Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 COVID-19 Vaccine in Healthy Younger and Older Participants" ($2.4M).